In a report released today, Laura Sutcliffe from UBS maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a price target of A$36.00. The company’s shares closed yesterday at $16.48.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Sutcliffe is a 4-star analyst with an average return of 7.0% and a 58.02% success rate. Sutcliffe covers the Healthcare sector, focusing on stocks such as CSL, Cochlear Limited, and Telix Pharmaceuticals Ltd..
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals Ltd. with a $21.24 average price target, which is a 28.92% upside from current levels. In a report released on March 21, Wilsons also maintained a Buy rating on the stock with a A$35.00 price target.
TLPPF market cap is currently $5.59B and has a P/E ratio of 173.19.
Read More on TLPPF:
- Telix Pharmaceuticals to Release Shares from Voluntary Escrow
- Telix Pharmaceuticals Expands into Latin America with Illuccix® Approval in Brazil
- Telix Pharmaceuticals Expands with New Share Issuance Following AI Platform Approval
- Telix Pharmaceuticals Announces Cessation of Securities
- Telix Pharmaceuticals Announces Director’s Interest Change
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue